Minimizes risk of damaging or perforating friable aortas
The only thoracic endograft to provide a safe, effective seal in angulated arch anatomy without these potentially damaging features
Maintains patency in small diameter thoracic aortas characteristic of young patients
Stent design maintains wall apposition in angulated arch anatomy without compromising tissue integrity
Help ensure flexibility and conformability in tortuous anatomy
Give physicians more options to match endograft to individual patient anatomies
Maintain patency in expected aortic flow velocities
BROAD TREATMENT RANGE
Intended Aortic Diameter (mm)
Device Diameters
The only thoracic endograft approved to treat patients with 16 mm thoracic aortas.
Intended Aortic Diameter (mm)
Aortic Diameter (mm)
GORE® TAG® Device
Conformable GORE® TAG® Device
The only thoracic endograft engineered to perform in 6-33% oversizing conditions.
No re-insertion is necessary if additional devices are required
Minimizes vessel trauma and the potential for rupture with multiple sheath insertions

Easy, single-step, twist-and-pull deployment
Sheathless, low-profile delivery catheter
Increased flexibility while navigating tortuous anatomy in the aortic arch
NEW
CURRENT
New flexible soft tip is designed to enhance trackability and delivery to target landing zone
Optimized visibility with radiopaque GORE® TAG® Device olives at both ends of the delivery catheter and radio dense marker embedded in the leading end of the catheter to aid in visualization
For more than a decade, Gore has worked alongside physicians in the evolution of TEVAR and the continued development of the GORE® TAG® Device. This collaboration has resulted in the distribution of more than 33,500 GORE® TAG® Devices for the treatment of more than 20,000 GORE® TAG® Device patients worldwide.
Aneurysm-Related Death Through Five Years
Percent Survival
Time Post Treatment(Months)
99-01 Open Surgical Control
99-01 GORE® TAG® Device
03-03 GORE® TAG® Device
04-02 GORE® TAG® Device
Freedom From Major Adverse Events Through Five Year
% Free from Major Adverse Event
Time Post Treatment(Months)
99-01 Open Surgical Control
99-01 GORE® TAG® Device
03-03 GORE® TAG® Device
04-02 GORE® TAG® Device
Enrollment
Follow-up
(all patients will be
followed through five years)
With the first clinical implant occuring in 1997, the GORE® TAG® Device has been studied in seven FDA-approved clinical studies, one European clinical trial and one European registry.
Having pioneered ePTFE graft technology 35 years ago, Gore continues to collaborate with physicians and scientists to create a robust and reliable design platform based on proven clinical performance
Featuring compliant polyurethane balloons, rapid inflation and deflation and uniform and simultaneous lobe inflation, this catheter allows for continuous flow around lobes while inflated, decreasing hemodynamic pressure on inflated balloons.
Available in two 18 Fr introducer sheath compatible sizes:
Small (BCM1634) for 16 - 34 mm vessel diameters
Large (BCL2645) for 26 - 42 mm vessel diameters
Minimizes blood loss through an innovative pressurized hemostatic valve
Accommodates multiple wires and catheters simultaneously through the valve with minimal blood loss
Facilitates hemostasis without intraprocedural manipulation of the valve